Topics

Drug Research

FDA strengthens warning on prescription anti-inflammatory medications

FDA strengthens warning on prescription anti-inflammatory medications

A decade's worth of research on nonsteroidal anti-inflammatory drugs, or NSAIDs,  has prompted the Food and Drug Administration to demand stiffer warnings on the labels of such prescription medications as celecoxib (marketed commercially as Celebrex) and diclofenac (Voltaren) about the increased risk of heart attacks and strokes in those taking the drugs. Prescription NSAID labels now will alert consumers that the higher risk of stroke or heart attack is evident in the first weeks a patient starts taking such drugs, that the risk appears to escalate at higher doses and with longer use, and that even people with no other cardiovascular risk factors are more likely to suffer...

Loading
69°